Beckley Psytech’s primary aim is to help patients in need by developing psychedelic medicines that offer significant improvements over currently available neuropsychiatric treatments.
To that end, we are building a pipeline of psychedelic compounds with distinct clinical attributes for mental and neurological diseases. Our development programs will focus on offering innovation and clear differentiation in the marketplace over existing treatment options.
Our R&D platform can be divided into three distinct though interrelated categories:
Compounds
private company
TSX.V: NUMI
Focus
Social
